

Contents

Contributors	xv
Preface	xvii

1. Bacterial infections in the lungs of patients with systemic autoimmune diseases	
<i>Ilaria Di Cataldo, Alfio Proietto, Irene Coppolino, Mario Francesco Cannavò, Attilio Cotroneo, Federica Lo Bello, Paolo Ruggeri, Ian M. Adcock and Gaetano Caramori</i>	
1. Introduction	1
2. Increased risk of bacterial infections in the lungs of patients with systemic autoimmune diseases	1
3. Pathogenesis of the increased susceptibility to bacterial infections in the lungs of patients with systemic autoimmune diseases	2
3.1 Effects on the immune response to bacteria of a concomitant immunosuppressive therapy	4
4. Clinical presentation, diagnostic approach, and treatment of the bacterial infections of the lungs in patients with systemic autoimmune diseases	6
5. Prevention of bacterial infections of the lungs in patients with systemic autoimmune diseases	6
6. Conclusions	7
7. Take home messages	7
References	8
2. Invasive fungal diseases in patients with rheumatic diseases	
<i>Spinello Antinori and Andrea Giacomelli</i>	
1. Introduction	13
2. Ubiquitous mycoses	17
2.1 Pneumocystosis	17
2.2 Cryptococcosis	22
2.3 Candidiasis	25
2.4 Aspergillosis	27
3. Endemic mycoses	29
3.1 Histoplasmosis	29

Contents

3.2	Coccidioidomycosis	32
3.3	Paracoccidioidomycosis	35
3.4	Talaromycosis	36
3.5	Blastomycosis	37
3.6	Sporotrichosis	38
	References	38
3.	Urinary tract infection and autoimmune diseases	
	<i>Ana Matas, Marc Xipell, Marta Bodro, Ricard Cervera and Luis F. Quintana</i>	
1.	Introduction	49
2.	Definitions and diagnosis	49
3.	Epidemiology and risk factors	50
4.	Etiology	51
5.	Clinical features	52
6.	Supplementary tests	53
6.1	Laboratory findings	53
6.2	Imaging techniques	53
7.	Management	54
7.1	Management of nonbacterial urinary tract infections	56
	Bibliography	56
4.	Viral hepatitis	
	<i>Andrew Ustianowski and Karen Devine</i>	
1.	Hepatitis A	59
1.1	Virology and pathogenesis	59
1.2	Natural history	61
1.3	Epidemiology and transmission	61
1.4	Diagnostics	62
1.5	Prevention and therapy	62
1.6	Rheumatologic presentations of hepatitis A	62
1.7	Influence of autoimmune conditions and treatments on hepatitis A	63
1.8	Conclusions	63
2.	Hepatitis B	63
2.1	HBV virology	63
2.2	Natural history	64
2.3	Epidemiology and transmission route	65
2.4	Diagnostics	65
2.5	Prevention and therapy	66
2.6	Rheumatologic presentations of hepatitis B infection	67
2.7	Influence of autoimmune conditions on hepatitis B	67
2.8	Influence of autoimmune treatments on hepatitis B	67
2.9	Management	70
2.10	Conclusions	70

3. HDV coinfection	71
4. Hepatitis C	71
4.1 Natural history	71
4.2 Global epidemiology and transmission route	72
4.3 Diagnostics	72
4.4 Prevention and therapy	72
4.5 Rheumatologic presentations of hepatitis C	73
4.6 Influence of autoimmune conditions on hepatitis C	73
4.7 Influence of rheumatological treatments on hepatitis C	74
4.8 Conclusions	74
5. Hepatitis E	74
5.1 Natural history	74
5.2 Epidemiology and transmission route	75
5.3 Diagnostics	75
5.4 Prevention and therapy	76
5.5 Rheumatologic presentations of hepatitis E	76
5.6 Influence of autoimmune treatments on hepatitis E	77
5.7 Conclusions	77
References	78
5. Mycobacteria and immunosuppression	
<i>Kevin L. Winthrop and Emilie Emilie Roy</i>	
1. Introduction	83
2. Tuberculosis	84
2.1 Epidemiology	84
2.2 Pathophysiology	85
2.3 Clinical presentation	86
2.4 Diagnosis	87
2.5 Treatment	90
2.6 Follow-up	92
2.7 Nontuberculous Mycobacteria	92
2.8 Microbiology	93
2.9 Epidemiology	94
2.10 Pathophysiology	95
2.11 Particularities in autoimmune diseases	95
2.12 Clinical presentation	96
2.13 Diagnostic	97
2.14 Treatment	99
2.15 Prognosis	100
2.16 Prevention	101
3. Leprosy	101
4. Buruli Ulcer	102
5. Conclusion	103
References	103

6. The immunosuppressed traveler: infection risks with autoimmunity and immunosuppression, vaccinations, and general travel advice

Victoria Allen, Nicky Longley, James B. Galloway and Katie Bechman

1. Introduction	109
1.1 This chapter aims to	110
2. Risk assessment and travel medicine	110
2.1 Defining risk	110
2.2 Risk assessment framework	110
2.3 Person	111
2.4 Activities	111
2.5 Place	111
2.6 Time	111
2.7 Travelers visiting friends and relatives	112
3. Types of immunosuppression used in autoimmune disease and their mechanisms of action	112
3.1 Defining immunosuppression	112
3.2 Biological therapies	112
3.3 TNF-alpha inhibitors	113
3.4 TNF-alpha blockers and immunization	113
3.5 Rituximab	113
3.6 Nonbiological drugs	114
4. Immunosuppression for autoimmunity and travel medicine	114
4.1 Patients considered to have limited immunosuppression include	114
4.2 Patients considered to be at risk of significant immunosuppression include patients treated with the following	115
4.3 General implications of significant immunosuppression	115
5. Vaccination in the immunosuppressed traveler	115
5.1 General vaccine considerations with significant immunosuppression	115
5.2 Live vaccinations available in Europe	116
6. Vaccine preventable, travel-related infections in the significantly immunosuppressed traveler	117
6.1 Yellow Fever	117
6.2 Typhoid	118
6.3 Hepatitis A	118
6.4 Rabies	119
6.5 Meningococcal disease	120
6.6 Influenza	121
6.7 Japanese encephalitis	122
7. Vector-borne infections in the significantly immunosuppressed traveler	123
7.1 Mosquito bite avoidance	123
7.2 Tick-borne infections	124
7.3 Malaria	124
7.4 Chagas disease	125
7.5 Leishmaniasis	126

8. Other nonvaccine preventable infections	127
8.1 Travellers' diarrhea, food, and water hygiene	127
8.2 Hepatitis E	129
8.3 Strongyloidiasis	130
8.4 Fungal infections	131
8.5 Sexually transmitted infections	133
8.6 Emerging infectious diseases	133
9. Other travel considerations	134
9.1 Travel insurance	134
9.2 Preexisting medical conditions	134
9.3 Road traffic accidents	135
9.4 Venous thromboembolism	135
9.5 Sun exposure	136
10. Conclusions	136
References	136

7. Infections in systemic autoimmune diseases

Miriam Dixon-Zegeye and Andrew Rutherford

1. Introduction	143
2. Section 1: Patient factors	143
2.1 Age	143
2.2 Functional disability	144
2.3 Comorbidity	144
2.4 Smoking	145
2.5 Infection history	145
3. Section 2: Immunological dysfunction	146
3.1 Introduction	146
3.2 Adaptive immune system	146
3.3 Innate immunity	149
4. Conclusion	150
5. Section 3: Disease severity	151
5.1 Rheumatoid arthritis	151
5.2 Systemic lupus erythematosus	152
6. Section 4: Impact of drug therapy on infection risk	152
7. Conventional synthetic DMARDs	153
8. Corticosteroids	154
9. Biological therapies	154
10. Janus kinase inhibitors	156
11. Conclusions	156
12. Section 5: Outcomes	157
12.1 Anti-TNF- α	157
12.2 Immunotherapy in macrophage activation syndrome	158
13. Beneficial effect of biologics disease-modifying antirheumatic drugs on the risk of sepsis	158
13.1 Discontinuation of bDMARDs during a serious infection	158
References	159

8. Bone and joint bacterial infections in patients with rheumatoid arthritis

Ignazio Francesco Masala, Francesca Marino, Piercarlo Sarzi-Puttini and Fabiola Atzeni

1. Introduction	167
2. Bone and joint infections	167
3. Prosthetic joint infections	168
3.1 Definitions and classification	168
3.2 Etiological agents	168
3.3 Risk factors	169
4. Chronic osteomyelitis and implant-associated osteomyelitis of long bones	170
4.1 Definition and classification	170
4.2 Etiological agents and risk factors	170
5. Infections in rheumatoid arthritis patients and the use of drugs	171
5.1 Conventional disease-modifying antirheumatic drugs	171
5.2 Septic arthritis and perioperative joint infections	171
5.3 Biological drugs	172
5.4 Anti-TNF agents and septic arthritis and perioperative joint infections	172
5.5 Newer biological agents	173
5.6 Septic arthritis and perioperative joint infections	173
6. Conclusions	173
7. Take-home messages	174
Authors' contributions	174
Competing interests	174
References	174

9. Risk/benefit management in the infectious phase in systemic autoimmune rheumatic diseases

Manuel Pombo-Suarez and Juan J. Gomez-Reino

1. Introduction	179
2. Serious infections in patients treated with biologic disease modifying antirheumatic drugs	180
3. Opportunistic infection in patients treated with biologic disease modifying antirheumatic drugs	182
3.1 Tuberculosis in patients treated with biologic disease modifying antirheumatic drugs	183
3.2 Nontuberculous mycobacteria infections in patients treated with biologic disease modifying antirheumatic drugs	186
3.3 Salmonella species infection in patients treated with biologic disease modifying antirheumatic drugs	187
3.4 <i>Pneumocystis jirovecii</i> infection in patients treated with biologic disease modifying antirheumatic drugs	187

Contents

3.5	Varicella-zoster virus infection in patients treated with biologic disease modifying antirheumatic drugs	188
3.6	Hepatitis B infection in patients treated with biologic disease modifying antirheumatic drugs	190
3.7	Hepatitis C infection in patients treated with biologic disease modifying antirheumatic drugs	193
3.8	Listeria monocytogenes infection in patients treated with biologic disease modifying antirheumatic drugs	194
3.9	Mycosis infection in patients treated with biologic disease modifying antirheumatic drugs	195
4.	Summary	195
	References	196
	Index	205